Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Voorraadrapport

Marktkapitalisatie: US$9.1b

Intra-Cellular Therapies Beheer

Beheer criteriumcontroles 3/4

De CEO Intra-Cellular Therapies is Sharon Mates, benoemd in May2002, heeft een ambtstermijn van 22.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.09M, bestaande uit 8.8% salaris en 91.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.01% van de aandelen van het bedrijf, ter waarde $ 91.67M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.1 jaar en 10.8 jaar.

Belangrijke informatie

Sharon Mates

Algemeen directeur

US$10.1m

Totale compensatie

Percentage CEO-salaris8.8%
Dienstverband CEO22.5yrs
Eigendom CEO1.0%
Management gemiddelde ambtstermijn6.1yrs
Gemiddelde ambtstermijn bestuur10.8yrs

Recente managementupdates

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

Analyse CEO-vergoeding

Hoe is Sharon Mates's beloning veranderd ten opzichte van Intra-Cellular Therapies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$10mUS$892k

-US$140m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$228m

Dec 31 2022US$9mUS$849k

-US$256m

Sep 30 2022n/an/a

-US$298m

Jun 30 2022n/an/a

-US$321m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$7mUS$794k

-US$284m

Sep 30 2021n/an/a

-US$259m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$232m

Dec 31 2020US$5mUS$767k

-US$227m

Sep 30 2020n/an/a

-US$207m

Jun 30 2020n/an/a

-US$187m

Mar 31 2020n/an/a

-US$160m

Dec 31 2019US$5mUS$745k

-US$148m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$154m

Dec 31 2018US$4mUS$723k

-US$155m

Sep 30 2018n/an/a

-US$145m

Jun 30 2018n/an/a

-US$126m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$5mUS$702k

-US$98m

Compensatie versus markt: De totale vergoeding ($USD 10.09M ) Sharon } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.78M ).

Compensatie versus inkomsten: De vergoeding van Sharon is gestegen terwijl het bedrijf verliesgevend is.

CEO

Sharon Mates (71 yo)

22.5yrs

Tenure

US$10,086,413

Compensatie

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Sharon Mates
Co-Founder22.5yrsUS$10.09m1.01%
$ 91.7m
Michael Halstead
Presidentless than a yearUS$3.53m0%
$ 0
Suresh Durgam
Executive VP & Chief Medical Officer6.3yrsUS$3.51m0.019%
$ 1.7m
Mark Neumann
EVP & Chief Commercial Officer6.1yrsUS$3.54m0.028%
$ 2.5m
Robert Davis
Senior VP & Chief Scientific Officer9yrsUS$2.13mgeen gegevens
Juan Sanchez
Vice President of Corporate Communications & Investor Relations10.7yrsUS$1.38mgeen gegevens
Karen Sheehy
Senior VP & Chief Compliance Officer5.3yrsgeen gegevensgeen gegevens
John Condon
Senior Vice Presidentno datageen gegevensgeen gegevens
Michael Olchaskey
Senior VP & Head of Regulatory Affairs6.2yrsgeen gegevensgeen gegevens
John Bardi
Senior VP of Market Access5.7yrsgeen gegevensgeen gegevens
Willie Earley
Senior VP & Head of Clinical Development2.6yrsgeen gegevensgeen gegevens

6.1yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ITCI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Sharon Mates
Co-Founder11.3yrsUS$10.09m1.01%
$ 91.7m
Rory Riggs
Independent Director10.8yrsUS$470.51k0.11%
$ 10.0m
Robert Van Nostrand
Lead Independent Director10.8yrsUS$507.58k0.011%
$ 971.6k
Joel Marcus
Independent Director11.3yrsUS$473.34k0.039%
$ 3.5m
Carol Tamminga
Chairman of Medical Advisory Boardno datageen gegevensgeen gegevens
John Kane
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Jeffrey Lieberman
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Christoph Correll
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Donald Goff
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Eduardo Salas
Independent Director2.6yrsUS$461.30k0.0015%
$ 134.4k

10.8yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ITCI zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.8 jaar).